Pure Global AI
NCT06335160Not yet recruiting

Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Clinical Study to Evaluate the Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
Tanta UniversityClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Ulcerative Colitis
Drug/Device/Intervention
Mebendazole
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tanta University
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
May 01, 2025
Enrollment
46 participants
Primary outcome

change in disease activity,change in Partial Mayo Scoring Index (PMSI) assessment for Ulcerative Colitis Activity

Summary

To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative
 colitis treated with mesalamine

ICD-10 classifications
Ulcerative colitisOther ulcerative colitisUlcerative colitis, unspecifiedArthropathy in ulcerative colitisJuvenile arthritis in ulcerative colitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06335160
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06335160 through Pure Global AI's free database. This phase not specified trial is sponsored by Tanta University and is currently Not yet recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 46 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.